These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 38976087

  • 1. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y, Ando M, Watanabe H, Ono M.
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [Abstract] [Full Text] [Related]

  • 2. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 3. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
    Xiao D, Duan X, Gan Q, Zhang X, Zhang J.
    Molecules; 2020 Nov 26; 25(23):. PubMed ID: 33256058
    [Abstract] [Full Text] [Related]

  • 4. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
    Kimura H, Sampei S, Matsuoka D, Harada N, Watanabe H, Arimitsu K, Ono M, Saji H.
    Bioorg Med Chem; 2016 May 15; 24(10):2251-6. PubMed ID: 27073053
    [Abstract] [Full Text] [Related]

  • 5. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 15; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 6. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 15; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 7. Development of a hydroxamamide-based bifunctional chelating agent to prepare technetium-99m-labeled bivalent ligand probes.
    Shimizu Y, Ando M, Iikuni S, Watanabe H, Ono M.
    Sci Rep; 2021 Sep 21; 11(1):18714. PubMed ID: 34548586
    [Abstract] [Full Text] [Related]

  • 8. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 21; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 9. Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA).
    Bezverkhniaia E, Kanellopoulos P, Abouzayed A, Larkina M, Oroujeni M, Vorobyeva A, Rosenström U, Tolmachev V, Orlova A.
    Int J Mol Sci; 2023 Dec 12; 24(24):. PubMed ID: 38139219
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and Radiolabeling of Glu-Urea-Lys with 99mTc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation as Prostate-Specific Membrane Antigen Inhibitor.
    Hatamabadi D, Joukar S, Shakeri P, Balalaie S, Yazdani A, Khoramjouy M, Mazidi SM, Kobarfard F, Mosayebnia M, Bozorgchami N, Ahmadi M, Ayyoubzadeh SM, Shahhosseini S.
    Cancer Biother Radiopharm; 2023 Sep 12; 38(7):486-496. PubMed ID: 37578479
    [Abstract] [Full Text] [Related]

  • 11. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.
    J Med Chem; 2013 Aug 08; 56(15):6108-21. PubMed ID: 23799782
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H.
    J Nucl Med; 2016 Dec 08; 57(12):1978-1984. PubMed ID: 27417647
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun 08; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and Evaluation of 99mTc-Labeled DPro-Gly-Containing Tracers Targeting PSMA.
    Li Z, Jiang Y, Ruan Q, Yin G, Han P, Duan X, Zhang J.
    Mol Pharm; 2024 Oct 07; 21(10):5305-5314. PubMed ID: 39298677
    [Abstract] [Full Text] [Related]

  • 15. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M, D'Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, Arezumand R, Morovvati H, Lahoutte T, Muyldermans S, Devoogdt N.
    Contrast Media Mol Imaging; 2014 Oct 07; 9(3):211-20. PubMed ID: 24700748
    [Abstract] [Full Text] [Related]

  • 16. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.
    Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U.
    J Nucl Med; 2015 Feb 07; 56(2):293-8. PubMed ID: 25613537
    [Abstract] [Full Text] [Related]

  • 17. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.
    J Nucl Med; 2014 Nov 07; 55(11):1791-8. PubMed ID: 25342385
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
    Bandari RP, Jiang Z, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ.
    Nucl Med Biol; 2014 Apr 07; 41(4):355-63. PubMed ID: 24508213
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and preclinical evaluation of the 177Lu-DOTA-PSMA(inhibitor)-Lys3-bombesin heterodimer designed as a radiotheranostic probe for prostate cancer.
    Escudero-Castellanos A, Ocampo-García B, Ferro-Flores G, Santos-Cuevas C, Morales-Ávila E, Luna-Gutiérrez M, Isaac-Olivé K.
    Nucl Med Commun; 2019 Mar 07; 40(3):278-286. PubMed ID: 30763290
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.
    Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.
    Eur J Nucl Med Mol Imaging; 2017 Apr 07; 44(4):647-661. PubMed ID: 27847991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.